- Home
- SEED vs NRXS Comparison
SEED vs NRXS Comparison
Compare SEED & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEED
- NRXS
- Stock Information
- Founded
- SEED 1997
- NRXS 2011
- Country
- SEED China
- NRXS United States
- Employees
- SEED N/A
- NRXS N/A
- Industry
- SEED Farming/Seeds/Milling
- NRXS
- Sector
- SEED Consumer Staples
- NRXS
- Exchange
- SEED Nasdaq
- NRXS Nasdaq
- Market Cap
- SEED 18.0M
- NRXS 20.9M
- IPO Year
- SEED N/A
- NRXS 2023
- Fundamental
- Price
- SEED $2.58
- NRXS $3.16
- Analyst Decision
- SEED
- NRXS
- Analyst Count
- SEED 0
- NRXS 0
- Target Price
- SEED N/A
- NRXS N/A
- AVG Volume (30 Days)
- SEED 59.3K
- NRXS 5.8K
- Earning Date
- SEED 09-27-2024
- NRXS 08-09-2024
- Dividend Yield
- SEED N/A
- NRXS N/A
- EPS Growth
- SEED N/A
- NRXS N/A
- EPS
- SEED 1.21
- NRXS N/A
- Revenue
- SEED $16,516,031.00
- NRXS $2,267,053.00
- Revenue This Year
- SEED N/A
- NRXS $383.16
- Revenue Next Year
- SEED N/A
- NRXS N/A
- P/E Ratio
- SEED $2.06
- NRXS N/A
- Revenue Growth
- SEED 64.93
- NRXS N/A
- 52 Week Low
- SEED $1.37
- NRXS $1.80
- 52 Week High
- SEED $6.38
- NRXS $5.24
- Technical
- Relative Strength Index (RSI)
- SEED 51.55
- NRXS 44.49
- Support Level
- SEED $2.40
- NRXS $2.93
- Resistance Level
- SEED $2.73
- NRXS $3.25
- Average True Range (ATR)
- SEED 0.19
- NRXS 0.10
- MACD
- SEED 0.04
- NRXS -0.01
- Stochastic Oscillator
- SEED 60.00
- NRXS 13.85
About SEED Origin Agritech Limited
Origin Agritech Ltd is a Chinese agricultural technology company. In crop seed biotechnologies, the company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).